UE-2343 is under clinical development by Actinogen Medical and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how UE-2343’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UE-2343 overview
UE-2343 (Xanamem) is under development for the treatment of dementia associated with Alzheimer's disease (AD), post-traumatic stress disorder, post-myocardial infarction, diabetes cognitive impairment, mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and other cognitive diseases. It is formulated as a gelatin capsule and administered orally. UE-2343 is a small molecule amido-isothiazole derivative. The drug candidate targets 11-beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). It was also under development for the treatment of fragile X syndrome (FXS).
Actinogen Medical overview
Actinogen Medical Limited (Actinogen) is a clinical-stage biotechnology company. The company provides treatment of alzheimer’s disease and age-related neurodegenerative diseases. It also involved in treating cognitive impairment in chronic neurodegenerative diseases through the inhibition of cortisol production. It’s xanamem is a drug under development for the treatment of alzheimer’s disease, which is designed to block the production of cortisol in the brain. Actinogen focuses on Xanamem in the clinical areas, including post traumatic stress disorder (PTSD), schizophrenia, and depression. Actinogen is headquartered in Sydney, Australia .
For a complete picture of UE-2343’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
